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Almost ten years ago, activism and
public protest resulted in a landmark
victory for the access to medicines move-
ment, when 39 of the world’s leading
pharmaceutical companies dropped their
collective lawsuit against the South African
government for attempting to legalize the
importation of cheaper generic versions of
drugs [1]. Following a settlement, medica-
tion prices—including those for antiretro-
virals to treat the millions of South
Africans with HIV/AIDS—dropped, and
public pressure on the pharmaceutical
industry was hailed a success [2]. A decade
later it’s time again for action—to hold
drug companies accountable for their
human rights responsibilities to make
medicines available and accessible to those
in need.
As part of this effort, PLoS Medicine
publishes three unique perspectives on the
question of whether drug companies are
living up to their human rights responsi-
bilities. Sofia Gruskin and Zyde Raad
from the Harvard School of Public Health
say more assessment is needed of such
obligations [3]; Geralyn Ritter, Vice
President of Global Health Policy and
Corporate Social Responsibility at Merck
& Co., argues that multiple stakeholders
could do more to help States deliver the
right to health [4]; and Paul Hunt and
Rajat Khosla offer their reflections [5] on
Mr. Hunt’s work as the UN Special
Rapporteur on the right to the highest
attainable state of health (2002–2008),
which culminated in the first ‘‘Human
Rights Guidelines for Pharmaceutical
Companies’’ [6]. This PLoS Medicine De-
bate comes two years after the release of
the Guidelines and a year after Mr. Hunt’s
report [7] on his invited mission to review
the policies and practices of GlaxoS-
mithKline (GSK) was submitted to the
UN Human Rights Council. Together
these perspectives and reports make clear
that the responsibilities of pharmaceutical
companies go beyond stakeholder value to
encompass human rights. What is also
clear is that more accountability is now
needed.
The Guidelines on human rights re-
sponsibilities of drug companies—based
upon an extensive and consultative process
with multiple stakeholders—include re-
sponsibilities for transparency, manage-
ment, monitoring and accountability, pric-
ing, and ethical marketing. They identify
best practice as including access to med-
icines, differential pricing between and
within countries, commercial voluntary
licensing that allows for the production of
cheaper generics, investment into research
and development (R&D) of neglected
diseases, and engagement in public–pri-
vate partnerships. The Guidelines also
recommend against lobbying for more
protection in intellectual property laws,
applying for patents for trivial modifica-
tions of existing medicines, inappropriate
drug promotion, and excessive pricing.
Indeed, a most notable aspect of the Hunt
Report is its revelation that many of the
obstacles States face in delivering the right
to health to their citizens are created by
these very drug company practices [7].
The chief proposition in the Guidelines
is that pharmaceutical companies, by
virtue of being granted by society the
monopoly and power to develop medi-
cines, hold that power (the patent) with
express conditions. And these conditions
include human rights responsibilities to
make medicines available and accessible.
As Hans Hogerzeil, WHO Director of
Essential Medicines and Pharmaceutical
Policies, was quoted recently as saying, not
providing new drugs available to those
who need them ‘‘breaks the social contract
and works against the duty to promote
human rights—as the company that holds
the patent is basically the only entity that
can legally do so’’ [8]. At the same time
that the 825 billion dollar global pharma-
ceutical industry operates as society’s chief
developer and purveyor of life-saving
medicine, two billion people around the
world lack access to essential medicines.
Such a persistent perversity demands more
outrage.
Unfortunately, the pharmaceutical com-
panies that now do acknowledge the
importance of principles related to human
rights tend to blunt their own responsibil-
ities by instead emphasizing their corporate
social responsibility initiatives, employment
standards, global health programmes, and
participation in drug donation schemes,
voluntary price reductions, or international
business groups like the UN Global Com-
pact and the Business Leaders Initiative on
Human Rights (BLLIHR) [9–12]—not
explicitly human rights activities. Indeed,
there is danger in pharmaceutical compa-
nies’ persistent assertions that the primary
responsibility for delivering the right to
health lies with the State and that their role
is merely supportive—as reflected in the
Merck perspective published today in PLoS
Medicine [4]—as this argument allows the
industry to exculpate itself from its own
human rights responsibilities.
Klaus Leisberger, President of the
Novartis Foundation for Sustainable
Development, is a leading advocate of
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pharmaceutical companies, but neverthe-
less writes that ‘‘no private enterprise has
the societal mandate or the organizational
capabilities to feed the poor or provide
health care to the sick’’ [13]. ‘‘Enlight-
ened’’ pharmaceutical companies, he says,
can respect and even protect the right to
health of their employees, for example.
But beyond that, in terms of delivering the
right to health, he argues that this
responsibility ‘‘cannot be more than a
very limited contribution to overcoming
the challenges that we all face on a global
level.’’ And indeed major companies in
their responses to the Guidelines argued
that their role and human rights respon-
sibilities are not adequately defined
[14,15]. In contrast, independent observ-
ers have stated that these expectations are
in fact well delineated [16].
So how well are drug companies doing?
Several exercises are available that shed
some light on the question. The most
important of these, the Access to Medicines
Index (http://www.accesstomedicineindex.
org/), provides an unprecedented and
independent comparative analysis of 27
top drug companies on measures of com-
mitments, performance, transparency, and
R&D in relation to access to medicines. Its
2010 Report ranks companies in several
areas and details improvements since
2008—this year GSK topped the list again,
and appears to be a consistently viewed
industry leader. Merck & Co. and Novartis
were ranked two and three in 2010, with
Pfizer and Gilead emerging as the most
improved since 2008. The Index concludes
that many more companies are participat-
ing in initiatives to improve access to
medicines and are becoming more trans-
parent and cooperative in sharing informa-
tion but that the need for medicines across a
range of infectious and non-communicable
diseases remain substantial and is growing.
(Notably, the Index does not examine
company performance against best practic-
es, but instead against other companies.)
Other analyses, by the George Institute,
the UK Department of International
Development, and others [5] demonstrate
some progress in access to medicines and
many areas where improvement is needed.
But none of these audits, including the
Access to Medicine Index, ‘‘frame the
performance indicators in human rights
terms’’ and none ‘‘explicitly advocate a
requirement for accountability against
human rights standards,’’ emphasised Paul
Hunt in an interview with PLoS Medicine.
What type of accountability is needed?
The importance and significance of
accountability in this area cannot be
overstated. As Helen Potts argues, ac-
countability is not merely ‘‘responsiveness,
responsibility, answerability or evaluation’’
[17]. Where the pharmaceutical industry
and access to medicines intersect, account-
ability is something much more than that
and must go to the core of the business
activity. Paul Hunt’s work [5] highlights
the critical step of companies creating
independent, transparent mechanisms to
monitor and publicly document their own
activities. We agree. Beyond an add-on or
peripheral activity, the acknowledgement
and promotion of human rights must
become a regular, integrated aspect of
the work of pharmaceutical companies.
Better yet would also be an external,
international body charged explicitly with
monitoring the policies and practices of
pharmaceutical companies and reporting
publicly on the discharge of their right-to-
health responsibilities.
The challenge for the pharmaceutical
industry is to develop viable business
models that allow for profit whilst respect-
ing and promoting human rights. Phar-
maceutical companies are tremendously
innovative entities that abhor bad public-
ity, so the incentive is there for stimulating
creative thinking under public pressure.
The human rights guidelines and respon-
sibilities are now clear; the monitoring and
accountability must step up in earnest.
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